– USA, MA – Indigo Agriculture, a company dedicated to harnessing nature to help farmers sustainably feed the planet, announced the closing of $360M in additional financing bringing the total Series F preferred financing to $535M.
The round included participation from new and existing investors, including the Alaska Permanent Fund as well as the founder and initial investor of Indigo, Flagship Pioneering.
The company also announced the appointment of Stéphane Bancel, Founding CEO of Moderna Inc. (NASDAQ: MRNA), a biotechnology company pioneering messenger RNA therapeutics and vaccines, to the Board of Directors.
“Stéphane’s pioneering approach to using messenger RNA to create a new generation of medicines for patients – particularly the work he is leading to bring forth one of the first potential vaccines against the global COVID-19 pandemic – highlights his commitment to driving transformational change by embracing innovation and new ways of thinking,” said Board Chairman, Robert Berendes. “His demonstrated leadership will further propel Indigo through its next phase of growth and discovery.”
Accelerating Indigo’s vision to improve the environmental sustainability of farming, the profitability of farmers and the health of consumers, the capital will be used to scale and integrate Indigo’s core lines of business: Indigo Marketplace, Indigo Carbon, Indigo Transport, Digital Agronomy, and Indigo Microbials.
“Indigo’s offerings enable growers to get paid more for quality and sustainability while harnessing the potential of agriculture to address climate change,” said CEO, David Perry, Indigo. “One of these offerings, Indigo Marketplace, a platform that directly connects farmers with grain buyers, has completed over $1B in transactions since launching in September 2018.”
About Stéphane Bancel
Bancel has served as the CEO of Moderna since October 2011 and as a member of Moderna’s board of directors since March 2011. As CEO of Moderna, Bancel has led the accelerated development and discovery of the first vaccine candidate, mRNA-1273, against COVID-19 to enter human clinical trials in the United States. Before joining Moderna, Bancel served for five years as CEO of the French diagnostics company bioMérieux SA. From July 2000 to March 2006, he served in various roles at Eli Lilly and Company, including as Managing Director, Belgium and as Executive Director, Global Manufacturing Strategy and Supply Chain. Prior to Eli Lilly, Bancel served as Asia-Pacific Sales and Marketing Director for bioMérieux.
“Through technological and scientific innovation, Indigo has the potential to revolutionize the agriculture industry and directly address climate change, one of the greatest threats of our time,” said Bancel. “As a new member of Indigo’s Board of Directors, I am looking forward to applying insights and learnings gained throughout my career in medical science to furthering Indigo’s efforts to improve agriculture for the benefit of people and the planet.”
About Indigo Agriculture
Indigo improves grower profitability, environmental sustainability, and consumer health through the use of natural microbiology and digital technologies. The company’s scientific discoveries and digital platforms benefit tens of thousands of growers across millions of acres. Working across the supply chain, Indigo is furthering its mission of harnessing nature to help farmers sustainably feed the planet. In 2019, Indigo established The Terraton Initiative, a global effort to draw down one trillion tons of atmospheric carbon dioxide through agricultural soils. Ranked #1 on CNBC’s Disruptor 50 list in 2019, Indigo is headquartered in Boston, MA, with additional offices in Memphis, TN; Research Triangle Park, NC; South America; and Basel, Switzerland.
For more information: https://www.indigoag.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.